Drug shortages in developed countries—reasons, therapeutic consequences, and handling
Abstract
Drug shortages in developed countries pose a serious public health problem and have far-reaching implications for healthcare providers and their patients. Given the current state of the market, with the limited number of manufacturers and the array of manufacturing quality issues, drug shortages have become a global concern, forcing regulatory authorities to explore and implement strategies to prevent and mitigate drug shortages.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple factors contribute to medicine shortages, including manufacturing and quality problems, production delays, lack of manufacturing capacity, shortage of raw materials, political instability, profitability issues, long lead times, delays in awarding tenders, absence of national contracts on regional code lists, failure of suppliers to meet demand, and failure to pay suppliers.
“Some of the contributing factors to the shortage of medicines include manufacturing and quality problems, production delays, lack of manufacturing capacity, shortage of raw materials, political instability, and profitability issues [5, 6, 8, 9, 18].”
From Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications (2020) · cites this paper as [20]
Cited by
Sorted by citations
Modisakeng, C., Matlala, M., Godman, B., & Meyer, J. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05080-1 · Cited by 130 · see citing works
“Other factors include long lead times, delays in awarding tenders, absence of national contracts on the regional code lists of medicines, the failure of suppliers to meet demand, and the failure to pay suppliers [2, 19, 20].”
BackgroundBochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00942 · Cited by 112 · see citing works
“…ongoing collaborative relationships among all the stakeholders (including manufacturers and professional organizations) and also internally (within an organization), as well as having keen foresight and acting proactively, as opposed to just reactively, to a given situation (Dill and Ahn, 2014).”
BackgroundYang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., & Fang, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165183 · Cited by 70 · see citing works
- Authors
- Dill, S., & Ahn, J.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Dill, Susie
- ORCID
- Ahn, Jin
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2014-09-18
- Volume
- 70
- Issue
- 12
- Pages
- 1405-1412
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2054060918
- Cited by
- 66
- References
- 0
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 9 · 2023: 12 · 2022: 6 · 2021: 11 · 2020: 7 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 3
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- drug shortages, pharmaceutical supply chain, production quality, regulatory strategy, public health impact, healthcare workers, developed countries
- MeSH terms
- Canada, Drug Industry, Drug Therapy, Pharmaceutical Preparations, European Union, Humans, Developed Countries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
